RECEF Stock Price, Chart, Stats & News

Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E. coli and S. aureus bacteria, critically, even their antibiotic-resistant 'superbug' forms.